Treatment of sexually transmitted bacterial diseases in pregnant women

Drugs

Volumn 59, Issue 3, 2000, Pages 477-485

  Donders, Gilbert G G ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; BENZATHINE PENICILLIN; CEFIXIME; CEFTRIAXONE; CIPROFLOXACIN; CLINDAMYCIN; ERYTHROMYCIN; METRONIDAZOLE; OFLOXACIN; ORNIDAZOLE; PENICILLIN V; TINIDAZOLE; URINARY TRACT ANTIINFECTIVE AGENT;

CHLAMYDIASIS; DRUG CONTRAINDICATION; DRUG HYPERSENSITIVITY; FEMALE; FETUS RISK; GONORRHEA; HAEMOPHILUS DUCREYI; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PENICILLIN ALLERGY; PREGNANCY; PREMATURE LABOR; REVIEW; SEXUALLY TRANSMITTED DISEASE; SYPHILIS; TERATOGENICITY; TRICHOMONAS VAGINALIS; ULCUS MOLLE; URETHRITIS; VAGINITIS;

BACTERIA (MICROORGANISMS); HAEMOPHILUS DUCREYI; HUMAN IMMUNODEFICIENCY VIRUS; TRICHOMONAS VAGINALIS;

EID: 0034048684     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200059030-00005     Document Type: Review

References (48)

1. 1. Donders GGG, Desmyter J, De Wet GH, et al. The association of gonorrhoea and syphilis with premature birth and low birth weight. Genitourin Med 1993; 69: 98-101
2. 2. Donders GGG, Desmyter J, Hooft P, et al. Apparent failure of one injection of benzathine penicillin G for syphilis during pregnancy in human immunodeficiency virus-negative African women. Sex Transm Dis 1997; 24: 96-101
3. 3. Stray-Pedersen B. Cost-benefit analysis of a prenatal preventive programme against congenital syphilis. NIPH Ann 1980; 48: 57-66
4. 4. Centers for Disease Control and Prevention. Guidelines and treatment of sexually transmitted diseases: MMWR recommendations and report. Atlanta (GA): US Department of Health and Human Services, 1998
5. 5. Alexander JM, Sheffield JS, Sanchez PJ, et al. Efficacy of treatment for syphilis in pregnancy. Obstet Gynecol 1999; 93: 5-8
6. 6. Conover CS, Rend CA, Miler Jr GB, et al. Congenital syphilis after treatment of maternal syphilis with a penicillin regimen exceeding CDC guidelines. Infect Dis Obstet Gynecol 1998; 6: 134-7
7. 7. McFarlin BL, Bottoms SF, Dock BS, et al. Epidemic syphilis: maternal factors associated with congenital infection. Am J Obstet Gynecol 1994; 70: 535-40
8. 8. Wendel Jr GD, Sark BJ, Jamison RB, et al. Penicillin allergy and desensitization in serious infections in pregnancy. N Engl J Med 1985; 312: 1229-32
9. 9. Hook EW, Roddy RE, Handsfield HH. Ceftriaxone for incubating and early syphilis. J Infect Dis 1988; 158: 881-4
10. 10. Moorthy TT, Lee C-T, Lin K-B, et al. Ceftriaxone for treatment of primary syphilis in men: a preliminary study. Sex Transm Dis 1987; 14: 116-8
11. 11. Lind I, Arborio M, Bentzon MW, et al. The epidemiology of Neisseria gonorrhoeae isolates in Dakar, Sénégal 1982-1986: antimicrobial resistance, auxotypes and plasmid profiles. Genitourin Med 1991; 67: 107-13
12. 12. Kohl PK, Tu Y, Hostalek U, et al. Activity of cefixime against Neisseria gonorrhoeae. J Eur Acad Dermatol Venerol 1995; 4: 155-9
13. 13. Mandell GL, Douglas Jr RG, Bennett JE, et al. Treatment of sexually transmitted diseases. In: Mandell GL, Douglas RG, Bennett JE, editors. Principles and practice of infectious diseases: antimicrobial therapy 1996/1997. New York (NY): Churchill Livingstone, 1996: 92-6
14. 14. Judson FN. Treatment of uncomplicated gonorrhea with ceftriaxone: a review. Sex Transm Dis 1986; 13: 199-202
15. 15. Ueland K, Metcalfe J. Circulatory changes in pregnancy. Clin Obstet Gynecol 1975; 18: 41-56
16. 16. Zishka PA, Douglas JM. Immediate hypersensitivity reaction to single-dose parenteral ceftriaxone therapy for gonorrhea. Sex Transm Dis 1992; 18: 26-7
17. 17. Ingham B, Brentnall DW, Dale EA, et al. Arthropathy induced by antibacterial fused N-alkyl-4-pyridone-3-carboxylic acids. Toxicol Lett 1977; 6: 21-6
18. 18. Schaefer C, Amoura-Elefant E, Vial T, et al. Pregnancy outcome after prenatal quinolone exposure: evaluation of a case registry of the European Network of Teratology Information Services 5 (ENTIS). Eur J Obstet Gynecol Obstet Reprod Biol 1996; 69: 83-9
19. 19. Loebstein R, Addis A, Ho E, et al. Pregnancy outcome following gestational exposure to fluoroquinolones: a multicenter prospective controlled study. Antimicrob Agents Chemother 1998; 42: 1336-9
20. 20. Handsfield HH, McCormack WM, Hook III EW, et al. A comparison of single dose cefixime with ceftriaxone as treatment for uncomplicated gonorrhea. N Engl J Med 1991; 325: 1337-41
21. 21. Verdon MS, Douglas JM, Wiggins SD, et al. Treatment of uncomplicated gonorrhea with single doses of 200 mg cefixime. Sex Transm Dis 1993; 20: 290-3
22. 22. Handsfield HH, Dalu ZA, Martin DH, et al. Azythromycin Gonorrhoea study group: multicenter trial of single-dose azythromycin vs ceftriaxone in the treatment of uncomplicated gonorrhoea. Sex Transm Dis 1994; 21 107-11
23. 23. Waugh MA. Open study of the safety and efficacy of a single oral dose of azithromycin for the treatment of uncomplicated gonorrhea in men and women. J Antimicrob Chemother 1993; 31 Suppl. E: 193-8
24. 24. Steingrimsson O, Olafsson JH, Thorainsson H, et al. Single dose azithromycin treatment of gonorrhea and infection caused by C trachomatis and U urealyticum in men. Sex Transm Dis 1994; 21: 43-6
25. 25. Martin DH, Mroczkowski TF, Dalu ZA, et al. A controlled trial of a single dose of azythromycin for the treatment of Chlamydial urethritis and cervicitis. N Engl J Med 1992; 327: 921-5
26. 26. Worskowski KA, Johnson RB, Verdon M, et al. Azithromycin in chlamydial urethritis [letter]. JAMA 1993; 270: 1934-5
27. 27. Worskowski KA, Hook EW, Handsfield HH. Single dose cefixime plus azithromycin in the treatment of uncomplicated gonorrhoea and chlamydial infection [abstract]. 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 1992 Oct 11-14; Anaheim (CA), 340
28. 28. Edwards M, Rainwater K, Carter S, et al. Comparison of azythromycin and erythromycin for chlamydia cervicitis in pregnancy [abstract]. Am J Obstet Gynecol 1994; 84: 61-3
29. 29. Bush MR, Rosa C. Azythromycin and erythromycin in the treatment of cervical chlamydial infection during pregnancy. Obstet Gynecol 1994; 84: 61-3
30. 30. Crombleholme WR, Schachter J, Grossman M, et al. Amoxicillin therapy for Chlamydia trachomatis in pregnancy. Am J Obstet Gynecol 1990; 75: 752-6
31. 31. D'Allaire, Huddleston JF, Graves WL, et al. Initial and repeat screening for Chlamydia trachomatis during pregnancy. Infect Dis Obstet Gynecol 1998; 6: 116-22
32. 32. McGregor JA, French JI, Parker R, et al. Prevention of premature birth by screening and treatment for common genital tract infections. Am J Obstet Gynecol 1995; 173: 157-67
33. 33. Donders GGG, De Wet GH, Hooft P, et al. Lactobacilli in Pap smears, genital infection and pregnancy. Am J Perinatol 1993; 3: 17-25
34. 34. Struthers BJ. Metronidazole appears not to be a human teratogen: review of the literature. Infect Dis Obstet Gynecol 1997; 5: 326-35
35. 35. Hart G. Risk profiles and epidemiologic interrelationships of sexually transmitted diseases. Sex Transm Dis 1993; 20: 126-36
36. 36. Simoes JA, Camargo RP, Giraldo PC, et al. Association between prenatal complications and bacterial vaginosis in Brazilian pregnant women. Second International Meeting on Bacterial Vaginosis; 1998 Sept 17-19; Aspen (CO), 30
37. 37. Donders GGG. Microscopy of the bacterial vaginal flora on fresh vaginal smears. Infect Dis Obstet Gynecol 1999; 7: 177-9
38. 38. Donders GGG. Bacterial vaginosis during pregnancy: screen and treat [editorial]. Eur J Obstet Gynecol Reprod Med 1999; 83: 1-4
39. 39. Hay PE, Lamont RF, Taylor-Robinson, et al. Abnormal bacterial flora colonisation of the genital tract and subsequent delivery and late miscarriage. BMJ 1994; 308: 295-8
40. 40. Donders GGG, Van Bulck B, Caudron J, et al. Bacterial vaginosis and Mycoplasmata increase the risk of spontaneous first trimester abortion. Am J Obstet Gynecol. In press
41. 41. Boris J, Pahlson C, Larsson P-G. Six years observation after successful treatment of bacterial vaginosis. Infect Dis Obstet Gynecol 1997; 5: 297-302
42. 42. Cook RL, Relondo-Lopez V, Schmitt C, et al. Clinical, microbiological and biochemical factors in recurrent bacterial vaginosis. J Clin Microbiol 1992; 30: 870-7
43. 43. Moi H, Erkkola R, Jerve F, et al. Should male consorts of women with bacterial vaginosis be treated? Genitourin Med 1989; 65: 263-8
44. 44. Hallen A, Jarstrand C, Pahlson C. Treatment of bacterial vaginosis with lactobacilli. Sex Transm Dis 1992; 19: 146-8
45. 45. Hillier S, Krohn MA, Meyn L, et al. Recolonisation of the vagina with an exogenous strain of Lactobacillus crispatus. Second International Meeting on Bacterial Vaginosis; 1998 Sept 17-19; Aspen (CO), 18
46. 46. Lugo-Miro VI, Green M, Mazur L. Comparison of different metronidazole therapeutic regimens for bacterial vaginosis: a meta-analysis. JAMA 1992; 268: 92-5
47. 47. Dickerson MC, Johnston J, Delea TE, et al. The causal role for genital ulcer disease as a risk factor for transmission of human immunodeficiency virus. Sex Transm Dis 1996; 23 (5): 429-40
48. 48. Sewankambo N, Gray RH, Wawer MJ, et al. HIV-1 infection associated with abnormal vaginal flora morphology and bacterial vaginosis. Lancet 1997; 350: 546-50